Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment.

American Journal of Human Genetics
Francis J McMahonHusseini Manji

Abstract

Depressive disorders account for a large and increasing global burden of disease. Although the condition of many patients improves with medication, only a minority experience full remission, and patients whose condition responds to one medication may not have a response to others. Individual variation in antidepressant treatment outcome is, at present, unpredictable but may have a partial genetic basis. We searched for genetic predictors of treatment outcome in 1,953 patients with major depressive disorder who were treated with the antidepressant citalopram in the Sequenced Treatment Alternatives for Depression (STAR*D) study and were prospectively assessed. In a split-sample design, a selection of 68 candidate genes was genotyped, with 768 single-nucleotide-polymorphism markers chosen to detect common genetic variation. We detected significant and reproducible association between treatment outcome and a marker in HTR2A (P range 1 x 10(-6) to 3.7 x 10(-5) in the total sample). Other markers in HTR2A also showed evidence of association with treatment outcome in the total sample. HTR2A encodes the serotonin 2A receptor, which is downregulated by citalopram. Participants who were homozygous for the A allele had an 18% reduction in...Continue Reading

References

Dec 1, 1967·The British Journal of Social and Clinical Psychology·M Hamilton
May 1, 1980·The American Journal of Psychiatry·S L SternJ Mendels
Jun 1, 1993·Trends in Pharmacological Sciences·P P HumphreyD Hoyer
Aug 1, 1997·American Journal of Human Genetics·M Boehnke, N J Cox
Oct 28, 1998·Journal of Psychiatric Research·L FranchiniE Smeraldi
Jun 3, 2000·Genetics·J K PritchardP Donnelly
Nov 7, 2000·Biological Psychiatry·W C Drevets
May 1, 2001·Nature Medicine·H K ManjiD S Charney
Feb 28, 2002·American Journal of Epidemiology·W James Gauderman
Apr 5, 2002·Neuron·Eric J NestlerLisa M Monteggia
Jun 12, 2002·The International Journal of Neuropsychopharmacology·Cristina CusinEnrico Smeraldi
Jul 5, 2002·Psychotherapy and Psychosomatics·Maurizio FavaRajinder Judge
Oct 16, 2002·Journal of Psychosomatic Research·Paolo Cassano, Maurizio Fava
Feb 1, 1960·Journal of Neurology, Neurosurgery, and Psychiatry·M HAMILTON
Dec 19, 2003·American Journal of Human Genetics·Christopher S CarlsonDeborah A Nickerson
Dec 20, 2003·Nature·UNKNOWN International HapMap Consortium
Feb 18, 2004·Current Drug Targets. CNS and Neurological Disorders·J E Leysen
Mar 31, 2004·Molecular Psychiatry·E J PetersS P Hamilton
Apr 6, 2004·Controlled Clinical Trials·A John RushUNKNOWN STAR*D Investigators Group
Apr 14, 2004·Genome Research·Kevin L GundersonMark S Chee
May 4, 2004·The American Journal of Psychiatry·Anil K MalhotraJames L Kennedy
May 5, 2004·The British Journal of Psychiatry : the Journal of Mental Science·T B UstünC J L Murray
May 19, 2004·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·Paolo Cassano, Maurizio Fava
Aug 7, 2004·Bioinformatics·J C BarrettM J Daly
Sep 15, 2004·Biological Psychiatry·Michael J ParsonsAndrew J Makoff
Mar 2, 2005·European Journal of Nuclear Medicine and Molecular Imaging·K PeremansR Dierckx
Apr 19, 2005·American Journal of Human Genetics·Jacqueline K Wittke-ThompsonNancy J Cox
Apr 30, 2005·Pharmacogenetics and Genomics·Alessandro SerrettiRoberto Quartesan
Jul 20, 2005·Annals of Medicine·Nadine Norton, Michael J Owen
Jan 5, 2006·The American Journal of Psychiatry·Madhukar H TrivediUNKNOWN STAR*D Study Team

❮ Previous
Next ❯

Citations

Sep 28, 2007·Psychopharmacology·René HurlemannAndreas Bauer
Nov 26, 2010·Psychopharmacology·Gregory V Carr, Irwin Lucki
Apr 12, 2008·European Archives of Psychiatry and Clinical Neuroscience·Wolfgang Maier, Astrid Zobel
Apr 12, 2008·European Archives of Psychiatry and Clinical Neuroscience·Jürgen Fritze
Jan 5, 2010·European Archives of Psychiatry and Clinical Neuroscience·Astrid Zobel, Wolfgang Maier
Dec 8, 2010·Journal of Neural Transmission·Kadri AndreAri Illi
Sep 18, 2010·Current Psychiatry Reports·Falk W Lohoff
Oct 22, 2010·Current Psychiatry Reports·Andrew F LeuchterBarry D Lebowitz
Dec 17, 2009·Biological Psychiatry·Francis J McMahon
Sep 22, 2010·Molecular Psychiatry·X ZhangM G Caron
Aug 16, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sarah H LisanbyMark S George
Sep 19, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jose de Leon
Feb 22, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Roy H PerlisJordan W Smoller
Nov 20, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sonja HorstmannElisabeth B Binder
Mar 20, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Roy H PerlisFrancis J McMahon
Jun 6, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Roy H PerlisPhilip S Wang
Jul 6, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Eleanor MurphyFrancis J McMahon
Jul 5, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Brooke H MillerMathew T Pletcher
Apr 15, 2009·The Pharmacogenomics Journal·Rudolf UherIan Craig
Aug 30, 2008·Schizophrenia Bulletin·Maria J Arranz, Shitij Kapur
Dec 17, 2008·Pharmacogenetics and Genomics·Eric J PetersSteven P Hamilton
Feb 14, 2009·Pharmacogenetics and Genomics·Michael CabaneroFrancis J McMahon
Dec 31, 2010·Pharmacogenetics and Genomics·David A MrazekRichard M Weinshilboum
Dec 20, 2007·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Mugdha ThakurDavid B Matchar
Dec 20, 2007·International Clinical Psychopharmacology·John P FeighnerJeffrey S Freed
Sep 10, 2009·International Clinical Psychopharmacology·Alexandra Schosser, Siegfried Kasper
May 11, 2010·International Clinical Psychopharmacology·Magali NoroIsabelle Massat
Oct 16, 2009·Psychiatric Genetics·Sandra M VillafuerteMargit Burmeister
Jul 14, 2009·Psychiatric Genetics·Eleanor J MurphyMyrna M Weissman
Jan 24, 2007·Psychiatry and Clinical Neurosciences·Tadafumi Kato
Nov 3, 2009·Psychiatric Services : a Journal of the American Psychiatric Association·Gonzalo LajeFrancis J McMahon
Nov 28, 2013·BMC Complementary and Alternative Medicine·Abdiryim YusupHalmurat Upur
May 1, 2009·Human Genomics·Antonio DragoAlessandro Serretti
May 18, 2013·BMC Medicine·Uzoezi OzomaroCharles B Nemeroff

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.